Enanta Pharmaceuticals' (ENTA) "Buy" Rating Reiterated at HC Wainwright

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Wednesday, MarketBeat reports. They presently have a $20.00 price target on the biotechnology company's stock. HC Wainwright's target price points to a potential upside of 71.45% from the stock's current price.

Other research analysts have also issued reports about the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Wall Street Zen lowered shares of Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, August 22nd. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Enanta Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $21.00.

Enanta Pharmaceuticals Stock Down 2.8%

ENTA traded down $0.34 during trading on Wednesday, hitting $11.67. The company's stock had a trading volume of 80,647 shares, compared to its average volume of 203,373. Enanta Pharmaceuticals has a twelve month low of $7.05 and a twelve month high of $17.15. The stock's fifty day moving average price is $13.19 and its 200-day moving average price is $13.32. The firm has a market capitalization of $339.74 million, a P/E ratio of -4.85 and a beta of 0.93.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. The business had revenue of $14.36 million during the quarter, compared to analyst estimates of $16.76 million. Equities research analysts expect that Enanta Pharmaceuticals will post -2.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth $36,000. Legal & General Group Plc acquired a new position in Enanta Pharmaceuticals during the second quarter worth $41,000. Clearstead Trust LLC acquired a new position in Enanta Pharmaceuticals during the second quarter worth $74,000. Kingsview Wealth Management LLC acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth $168,000. Finally, Bank of America Corp DE acquired a new position in Enanta Pharmaceuticals during the second quarter worth $314,000. Institutional investors and hedge funds own 94.99% of the company's stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and other diseases. The company's research has primarily centered on antiviral medicines, including treatments for respiratory syncytial virus (RSV), hepatitis B, and other infectious diseases.

Enanta is best known for its role in the development of glecaprevir, a protease inhibitor used with pibrentasvir in AbbVie's Mavyret (also marketed as Maviret) treatment for chronic hepatitis C virus infection.